- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Medicare Advantage Premiums Expected to Be Mostly Unchanged in 2016
As enrollment in Medicare Advantage is expected to increase to a new all-time high for the sixth year in a row, CMS announced that Medicare Advantage premiums will remain stable in 2016.
As enrollment in Medicare Advantage (MA) is expected to increase to a new all-time high for the sixth year in a row, CMS announced that MA premiums will remain stable in 2016.
According to new information from CMS, the average MA premium will decrease from $32.91 in 2015 to $32.60 in 2016. Overall, 59% of enrollees will face no premium increase at all.
“Seniors and people with disabilities continue to experience stable premiums in Medicare health and drug plans while benefiting from a transparent and competitive marketplace,” Sean Cavanaugh, CMS deputy administrator and director of the Center for Medicare, said in a statement. “Medicare Advantage and prescription drug plans remain affordable and provide high quality care.”
Since the passage of the Affordable Care Act in 2010, MA premiums are expected to have decreased nearly 10% while enrollment increases by more than 50%. At approximately 17.4 million enrollees, MA represents one-third of the Medicare population.
Nearly two-thirds of MA enrollees are in plans with at least 4 stars for 2016, an indication that beneficiaries are receiving higher quality care—in 2009 just 17% of enrollees were in plans with 4 or more stars.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
